Amarantus Bioscience (AMBS) Stock Price, News & Analysis

Company Overview

Amarantus Bioscience Holdings, Inc. is a development-stage biotechnology company historically focused on therapies and diagnostic products for neurological and neurodegenerative diseases. Its research programs have addressed conditions including Alzheimer’s disease, Parkinson’s disease, and other disorders involving nerve-cell damage or dysfunction.

The company’s historical pipeline has included MANF, a protein-based therapeutic candidate intended to support the survival and protection of nerve cells, and eltoprazine, a small-molecule drug candidate investigated for neurological and behavioral conditions. Amarantus has also pursued diagnostic technologies, including LymPro, an assay designed to assist in the evaluation of Alzheimer’s disease, and NuroPro, a biomarker platform associated with neurodegenerative disease research.

Amarantus Bioscience Holdings has been associated with operations in the United States and has historically been led by Gerald E. Commissiong, who served as president and chief executive officer. Because publicly available information about the company’s more recent operations and development programs is limited, investors should consult the company’s latest filings and disclosures for current information.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 739,495 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:AMBS
• CIK: 1424812
• Web: www.amarantus.com
• Phone: (650) 862-5391
• Fax: 408-852-4427
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.74